Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?

Xi Wen Zhao; Taco W Kuijpers; Timo K van den Berg

doi:https://doi.org/10.1182/blood-2011-11-391367

Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?

Xi Wen Zhao, Taco W Kuijpers, Timo K van den Berg

Research output: Contribution to journal › Article › Academic › peer-review

21 Citations (Scopus)

Original language	English
Pages (from-to)	4333-4; author reply 4334-5
Journal	Blood
Volume	119
Issue number	18
DOIs	https://doi.org/10.1182/blood-2011-11-391367
Publication status	Published - 3 May 2012

Keywords

Animals
Antibodies/therapeutic use
CD47 Antigen/immunology
Humans
Lymphoma, Non-Hodgkin/pathology

Access to Document

https://doi.org/10.1182/blood-2011-11-391367

Cite this

@article{51ddcb175ba54466b89097f756a39576,

title = "Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?",

keywords = "Animals, Antibodies/therapeutic use, CD47 Antigen/immunology, Humans, Lymphoma, Non-Hodgkin/pathology",

author = "Zhao, {Xi Wen} and Kuijpers, {Taco W} and {van den Berg}, {Timo K}",

year = "2012",

month = may,

day = "3",

doi = "https://doi.org/10.1182/blood-2011-11-391367",

language = "English",

volume = "119",

pages = "4333--4; author reply 4334--5",

journal = "Blood",

issn = "0006-4971",